Frank Perez-Guerra named CEO of Gundersen Moundview Hospital and Clinics

Wisconsin-based Gundersen Health System announced Fran Perez-Guerra, MD, a veteran of the institution, as chief executive officer of the Gundersen Moundview Hospital and Clinics. 

Perez-Guerra brings to the role more than 20 years of experience within Gunderson Health System.

"Gundersen Health System has built a reputation over the years for doing the right thing for rural healthcare," Perez-Guerra said in a prepared statement. "Our partnerships with Critical Access Hospitals like Gundersen Moundview, the specialty services we provide close to home for patients, and working side-by-side with organizations and community groups to improve health and well-being are just a few examples of why I'm proud to work for Gundersen and why I'm excited to get to work for Gundersen Moundview, its staff and for our patients."

Perez-Guerra previously worked within the System in the areas of medical and support staff recruitment, employee and labor relations, and the Gundersen Child Care Center.

"Frank brings to Gundersen Moundview a great deal of experience working in rural healthcare, but also a unique perspective of Gundersen Health System and its resources," says Garith Steiner, vice president of the Gundersen Critical Access Hospitals and Clinics. "This background combined with Frank's ability to build and sustain positive relationships will mean really great things for Gundersen Moundview patients and the community."

""

As a senior news writer for TriMed, Subrata covers cardiology, clinical innovation and healthcare business. She has a master’s degree in communication management and 12 years of experience in journalism and public relations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.